Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases

An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases.

(2017) R. Dummer et al.   JOURNAL OF CLINICAL ONCOLOGY

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

(2012) Kim Margolin et al.   LANCET ONCOLOGY

Oral Availability and Brain Penetration of the B-RAFV600E Inhibitor Vemurafenib Can Be Enhanced by the P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Inhibitor Elacridar

(2012) Selvi Durmus et al.   MOLECULAR PHARMACEUTICS

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor Microenvironment in the Brain

(2012) Mihaela Lorger   Cancers

Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens

(2011) V Chiarion-Sileni et al.   BRITISH JOURNAL OF CANCER

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis

(2011) E. S. Park et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Multimodality treatment of brain metastases: an institutional survival analysis of 275 patients

(2011) Ameer L Elaimy et al.   World Journal of Surgical Oncology

Determinants of survival in patients with brain metastases from cutaneous melanoma

(2010) M Staudt et al.   BRITISH JOURNAL OF CANCER

Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis

(2010) Toshihiro Seike et al.   CLINICAL & EXPERIMENTAL METASTASIS

The role of the organ microenvironment in brain metastasis

(2010) Isaiah J. Fidler   SEMINARS IN CANCER BIOLOGY

Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma

(2009) M. A. Davies et al.   CLINICAL CANCER RESEARCH

Final Version of 2009 AJCC Melanoma Staging and Classification

(2009) Charles M. Balch et al.   JOURNAL OF CLINICAL ONCOLOGY

The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma

(2009) SubbaRao V. Madhunapantula et al.   Pigment Cell & Melanoma Research

Combined Inhibition of MAPK and mTOR Signaling Inhibits Growth, Induces Cell Death, and Abrogates Invasive Growth of Melanoma Cells

(2008) Konstantinos G. Lasithiotakis et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Inhibition of PI3K-AKT-mTOR Signaling Sensitizes Melanoma Cells to Cisplatin and Temozolomide

(2008) Tobias Sinnberg et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY